The therapeutic approach of blocking IL-1 using an antibody, Canakinumab, significantly reduced mortality rates in CAD patients (12, 62) but it also induced systemic off-target effects due to low circulating leukocyte counts (12), limiting the global targeting of IL-1. This evidence concerns the gene IL1B and coronary artery disorder.